- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07948772
A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy Comparators (INSPIRE AT)
INSPIRE AT: Longitudinal Study Comparing the Natural History of Ataxia Telangiectasia in Children to Healthy Comparators
The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Insmed Medical Information
- Telefonnummer: 1-844-446-7633
- E-mail: medicalinformation@insmed.com
Studiesteder
-
-
-
Nottingham, Det Forenede Kongerige, NG7 2UH
- Rekruttering
- GBR001
-
-
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- Ikke rekrutterer endnu
- USA004
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287-0005
- Rekruttering
- USA002
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- USA001
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030-3008
- Rekruttering
- USA003
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Participants who meet all the inclusion criteria and none of the exclusion criteria will be eligible for inclusion in their respective cohort as appropriate.
Beskrivelse
Inclusion Criteria for the AT Cohort:
- Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
- If three years to 10 years (<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
- Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver informed consent form.
Inclusion Criteria for the Healthy Comparator Cohort:
- Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.
Exclusion Criteria for the AT Cohort:
- Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in investigational trials, expanded access programs, or as a licensed drug are eligible.
- Previous treatment with a chemotherapeutic agent for cancer.
- Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.
Exclusion Criteria for the Healthy Comparator Cohort:
- Diagnosis of any form of AT.
- Previous treatment with a chemotherapeutic agent for cancer.
- Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: CASE_CONTROL
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
AT Cohort
Participants with confirmed AT at screening visit will be enrolled and followed for 24 months. |
|
Healthy Comparator Cohort
Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score
Tidsramme: Baseline up to Month 24
|
Baseline up to Month 24
|
|
AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score
Tidsramme: Baseline up to Month 24
|
Baseline up to Month 24
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Height
Tidsramme: Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Change From Baseline in Weight
Tidsramme: Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Percentage of Participants Achieving Pre-defined Developmental Goals as Assessed by Denver Developmental Screening Test (DDST-II)
Tidsramme: Up to Month 24
|
Up to Month 24
|
|
|
AT Cohort: Change From Baseline in Pediatric Quality of Life Inventory (Peds QL) Score Measured by the Pediatric Quality of Life Inventory
Tidsramme: Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Change From Baseline in Motor Activity Assessed by Wearable Device
Tidsramme: Baseline up to Month 24
|
A wearable accelerometer will capture participant's movements during their everyday activities at home. These data will be processed using specific algorithms to generate measurements that include total sedentary time and time spent in light, moderate and vigorous activity. |
Baseline up to Month 24
|
|
Change From Baseline in Arm Function Assessed by Hevelius Test
Tidsramme: Baseline up to Month 24
|
Baseline up to Month 24
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Study Director, Insmed Incorporated
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Primære immundefektsygdomme
- Neurologiske manifestationer
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Sygdomme i immunsystemet
- Immunologiske mangelsyndromer
- Neurokutane syndromer
- Dyskinesier
- DNA-reparation-mangellidelser
- Cerebellære sygdomme
- Cerebellar ataksi
- Spinocerebellære ataksier
- Ataksi
- Telangiektase
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Ataxia Telangiectasia
Andre undersøgelses-id-numre
- INS NHS AT001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .